Evidence map›Paper›PMID 24509607›Full record

ArticleHuman vaccines & immunotherapeutics2014

A recombinant chimeric protein containing B chains of ricin and abrin is an effective vaccine candidate.

Junhong Wang, Shan Gao, Tao Zhang, Lin Kang, Wuchun Cao, Na Xu, Wensen Liu, Jinglin Wang

Open access · bronzeAbstract read
In one paragraph

Article in Human vaccines & immunotherapeutics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 3 countries.

Junhong WangState Key Laboratory of Pathogen and Biosecurity; Institute of Microbiology and Epidemiology; Academy of Military Medical Sciences; Fengtai District, Beijing, PR China; Tianjin Key Lab for Biomarkers Occupational and Environmental Hazard; Medical College of Chinese People's Armed Police Force; Tianjin, PR China.
Shan GaoState Key Laboratory of Pathogen and Biosecurity; Institute of Microbiology and Epidemiology; Academy of Military Medical Sciences; Fengtai District, Beijing, PR China.
Tao ZhangState Key Laboratory of Pathogen and Biosecurity; Institute of Microbiology and Epidemiology; Academy of Military Medical Sciences; Fengtai District, Beijing, PR China.
Lin KangState Key Laboratory of Pathogen and Biosecurity; Institute of Microbiology and Epidemiology; Academy of Military Medical Sciences; Fengtai District, Beijing, PR China.
Wuchun CaoState Key Laboratory of Pathogen and Biosecurity; Institute of Microbiology and Epidemiology; Academy of Military Medical Sciences; Fengtai District, Beijing, PR China.
Na XuInstitute of Military Veterinary; Academy of Military Medical Sciences; Changchun, PR China.
Wensen LiuInstitute of Military Veterinary; Academy of Military Medical Sciences; Changchun, PR China.
Jinglin WangState Key Laboratory of Pathogen and Biosecurity; Institute of Microbiology and Epidemiology; Academy of Military Medical Sciences; Fengtai District, Beijing, PR China.
Academy of Military Medical Sciences · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Both ricin toxin (RT) and abrin toxin (AT) are 2 important toxin agents as potantial bioweapons. A dual subunit vaccine against RT and AT exposure is a promising option for developing prophylactic vaccination. In this study, we constructed a dual vaccine with RT B chain and AT B chain named RTB-ATB. The RTB-ATB chimeric protein was expressed in Escherichia coli (E. coli), and the purified protein was used to evaluate the immune response by a 2 × 2 × 2 × 2 factorial design. The main effects included dose of RTB-ATB, route of immunization injection, immunization time interval, and dose of native toxins challenge. For 2 × LD(50) challenge of RT or AT, 100% of the RTB-ATB immunized mice survived and regained or exceeded their initial weights within 10 days. For 4 × LD(50) challenge, different routes of immunization injection caused significant difference (P < 0.05), intraperitoneal (i.p.) administration of immunogen protected mice better than the subcutaneous (s.c.) administration. In conclusion, when administered i.p. to mice with 25 μg per mouse and immunization time interval Π in the absence of adjuvant, the chimeric protein elicited a stronger immune response and protected the animals from a dose of native toxins which was 4 times higher than their LD(50) in unvaccinated mice. Besides, the RTB-ATB chimeric protein could induce specific neutralizing antibodies against these 2 toxins. We anticipate that this study will open new possibilities in the preparation of RTB-ATB dual subunit vaccine against the exposure to deadly RT and AT.

Indexed as

AbrinAnimalsDisease Models, AnimalEscherichia coliFemaleGene ExpressionImmunizationMice, Inbred BALB CPoisoningRecombinant Fusion ProteinsRicinSurvival AnalysisVaccines, SubunitVaccines, SyntheticAbrinRecombinant Fusion ProteinsRicinVaccines, SubunitVaccines, SyntheticabrinB chainbioterrorismchimeric proteinimmunogenricinvaccine candidate

Identifiers

PMID24509607
PMCPMC4896596
OpenAlexW1993154953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.